miR-181a Upregulation and KLF6 Expression in Clear Cell Renal Cell Carcinoma
By: Joseph Cupolo
Posted: Tuesday, December 5, 2017
Although dysregulated expression of miR-181a has been found to play a role in tumorigenesis in many cancers, its role in clear cell renal cell carcinoma has not been identified. However, a study by Xu Zhang, MD, and colleagues at the Chinese People’s Liberation Army Medical School in Beijing may have shed some light on the upregulation of miR-181a in clear cell renal cell carcinoma. The study, published in Urologic Oncology, found a relationship between levels of miR-181a and KLF6 expression, suggesting that manipulating miR-181a “may provide a beneficial effect in the treatment of clear cell renal cell carcinoma.”
The investigators discovered that miR-181a expression was upregulated in clear cell renal cell carcinoma tissues and cell lines. They also noted that the expression level of miR-181a correlated with the tumor size, tumor/node/metastasis staging, and Fuhrman grade. “Overexpression of miR-181a led to reduced KLF6 mRNA and protein levels, whereas mutations of the potential miR-181a–binding sites in the KLF6 gene abrogated this inhibitory effect,” they explained.
Expression levels of miR-181a in samples of clear cell renal cell carcinoma tumors and adjacent nontumor tissues from 42 patients as well as in 786-O, 769-P, A498, and CAKI-1 clear cell renal cell carcinoma cell lines were determined by quantitative real-time polymerase chain reaction. Potential targets of miR-181a were predicted using bioinformatic approaches and then verified by using the luciferase reporter assay.